China Pharma Holdings (CPHI) Interest & Investment Income (2010 - 2026)

China Pharma Holdings (CPHI) has reported Interest & Investment Income for 17 consecutive years, with $81.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income fell 80.81% year-over-year to $81.0; the trailing twelve-month figure through Jun 2026 stood at $735.0 (down 82.87% YoY), and the FY2025 full-year result was $2003.0, down 69.84% from the prior year.
• Interest & Investment Income declined to $81.0 in Q2 2026 per CPHI's latest filing, from $147.0 in the prior quarter.
• Across five years, Interest & Investment Income topped out at $6655.0 in Q1 2022 and bottomed at $81.0 in Q2 2026.
• Historically, Interest & Investment Income has averaged $1457.2 across 5 years, with a median of $1157.0 in 2022.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income soared 1539.16% in 2022, then slumped 86.31% in 2026.
• Over 5 years, Interest & Investment Income stood at $1003.0 in 2022, then surged by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then sank by 84.04% to $213.0 in 2025, then sank by 61.97% to $81.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $81.0, $147.0, and $213.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.